BioRestorative Therapies (FRA:9OF) Net Income From Continuing Operations : €-11.23 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. BioRestorative Therapies's net income from continuing operations for the three months ended in Mar. 2025 was €-4.94 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was €-11.23 Mil.

BioRestorative Therapies Net Income From Continuing Operations Historical Data

The historical data trend for BioRestorative Therapies's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRestorative Therapies Net Income From Continuing Operations Chart

BioRestorative Therapies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

-9.27

-39.21

-12.48

-9.55

-8.58

BioRestorative Therapies Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial															-2.05	-3.74	-0.98	-1.56	-4.94

BioRestorative Therapies Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-11.23 Mil.

BioRestorative Therapies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (FRA:9OF) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

BRTX:USA

Address

40 Marcus Drive, Suite One, Melville, NY, USA, 11747

Website

https://www.biorestorative.com

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

BioRestorative Therapies Headlines

No Headlines